Edison Scientific, spun out of FutureHouse, is being tapped by the team behind Metsera to create new biotechs using AI agents. The article describes FutureHouse’s early fundraising attempts to commercialize agentic tools for drug discovery and its eventual spinout of Edison Scientific with $70 million in venture funding in late 2025. Edison’s model emphasizes scaling scientific discovery via autonomous reasoning agents, and the Metsera-linked effort signals continued appetite among investors and large pharma partners for agent-driven discovery platforms that can convert research inputs into candidate assets faster than conventional workflows.